MangTeng
Israeli biopharma company MediWound (NASDAQ:MDWD) said its wound care product NexoBrid has been commercially launched in the US through partner Vericel.
NexoBrid, also known as anacaulase-bcdb, is an enzymatic therapeutic for the non-surgical removal of non-viable tissue from patients who have sustained severe burns. The company said the product also helps preserve viable tissue, which can be damaged during the surgical removal of non-viable tissue, thereby potentially reducing the need for subsequent skin grafting.
The product has been approved in over 40 countries, including the US, EU and Japan, where is has been designated an orphan drug, the company said.
